Allena Pharmaceuticals

General Information

We are a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. We are focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. Our proprietary technological approach enables us to design and develop stable, non-absorbable oral enzyme therapies that remain in the gastrointestinal, or GI, tract, where the enzyme can degrade these metabolites, allowing for removal from the body through the bowel.

Employees: 29
Founded: 2011
Contact Information
Address One Newton Executive Park, Suite 202, Newton, MA 02459 US
Phone Number (617) 467-4577
Web Address
View Prospectus: Allena Pharmaceuticals
Financial Information
Market Cap $309.3mil
Revenues $0 mil (last 12 months)
Net Income $-22.7 mil (last 12 months)
IPO Profile
Symbol ALNA
Exchange NASDAQ
Shares (millions): 5.3
Price range $14.00 - $14.00
Est. $ Volume $74.7 mil
Manager / Joint Managers Credit Suisse/ Jefferies/ Cowen
CO-Managers Wedbush PacGrow
Expected To Trade: 11/2/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change